Contact us: (212) 604-9800

Injections in the Eye

Injections in the Eye

Intravitreal injections are commonly used to treat age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion.

This procedure is performed in the office and requires a local anesthetic.  Before the medicine is injected, the eye is cleaned with an antiseptic.  There may be a spot of blood on the white part of the eye where the injection is given.  This spot will usually resolve within two weeks.  Many times, patients may experience some irritation or scratchy sensation and some blurry vision after the injection.

 

Improvements in vision may occur as quickly as a few weeks or may take several injections.  Some patients will not experience any improvement in vision.  This does not indicate that the medication is not working, instead it may be the disease beginning to stabilize.

 

Medications for Injections

Eylea

Eylea injection, also known as aflibercept, is a medication that is used to treat the wet form of age-related macular degeneration, also known as AMD or ARMD. Age-related macular degeneration affects the macula, the part of the eye that provides sharp, central vision.

 

Eylea also slows the development of vascular endothelial growth factor, or VEGF, a protein that causes abnormal blood vessels to grow and leak, damaging the macula. By slowing the development of VEGF, Eylea aids in the prevention and reversal of vision loss experienced by those patients with macular degeneration. Unlike Avastin or Lucentis, Eylea binds with VEGF and has the potential to last longer than Avastin or Lucentis.

 

Approved by the Food and Drug Administration in 2011, Eylea was evaluated in two clinical trials with over 2,000 patients. Side effects that are most commonly reported for patients receiving Eylea include pain at the injection site, vitreous floaters, clouding of the lens of the eye, retinal detachment and an increase in intraocular pressure.


Lucentis

Lucentis, also known as ranibizumab injection, is a medication that is used to treat the wet form of age-related macular degeneration, also known as AMD or ARMD. Age-related macular degeneration affects the macula, the part of the eye that provides sharp, central vision. Lucentis also slows the development of vascular endothelial growth factor, or VEGF, a protein that causes abnormal blood vessels to grow and leak, damaging the macula. By slowing the development of VEGF, Lucentis aids in the prevention and reversal of vision loss experienced by those patients with macular degeneration. Lucentis was designed specifically for use in the eye and is typically administered once a month with an injection into the eye.

 

Prior to approval by the Food and Drug Administration in 2006, Lucentis was studied extensively in 10 clinical trials with over 5,000 patients and has been used to treat over 100,000 patients with AMD.

 

There are known side-effects in the use of Lucentis including detached retinas, and increase in intraocular pressure and inflammation and infection inside the eye.


Avastin

Avastin, also known as bevacizumab, is a medication that is used to treat age-related macular degeneration, also known as AMD, a debilitating eye disease. Avastin works by blocking the body from producing vascular endothelial growth factor, or VEGF, a protein that causes abnormal blood vessels to grow, damaging the macula. Avastin has been shown to improve vision when it is administered on a monthly basis.

 

The macula is the central part of the retina. The function of the macula is to provide central vision as well as visual detail. In the advanced stages of AMD, known as the wet form, blood vessels grow abnormally, leaking fluid and blood into the macula. Vision becomes obscured and patients experience a loss of central vision.

 

Avastin blocks the growth of abnormal blood vessels and leakage of fluid from the blood vessels. This reduces swelling in the macula, preventing further vision loss and even improving vision for some patients with AMD.

 

Originally developed to treat metastatic colorectal cancer, Avastin is FDA-approved for that purpose. Studies have shown that Avastin can effectively be used to treat AMD, resulting in increased vision. Ophthalmologists have been offering Avastin to their patients. Avastin is administered in a series of injections into the vitreous portion of the eye. Injections are usually scheduled 4-6 weeks apart.

To learn more about our Retina and Vision Services

To learn more about our Retina and Vision Services please contact us at
(212) 604-9800 today to schedule an appointment
retina specailists
  • RETINA SPECIALISTS
  • 20 West 13th Street New York, NY 10011
  • Telephone Number: (212) 604-9800
  • Fax: (212) 242- 4757